EUVIMEDEUVIMED entdecken
Crossref

Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation

Diego Mannhart, Mirko Lischer, Sven Knecht, Jeanne du Fay de Lavallaz, Ivo Strebel, Teodor Serban, David Vögeli, Beat Schaer, Stefan Osswald, Christian Mueller, Michael Kühne, Christian Sticherling und 1 weitere

JACC: Clinical Electrophysiology · 2023-02 · 9 (2) · 232-242

DOI: 10.1016/j.jacep.2022.09.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2023-02. Verfasst von Diego Mannhart und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, Universi…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Wearable Electronic Devices. Die Arbeit wurde bisher 173-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Beckman Coulter Foundation, Boston Scientific Corporation, MicroPort.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multiple smart devices capable to detect atrial fibrillation (AF) are presently available. Sensitivity and specificity for the detection of AF may differ between available smart devices, and this has not yet been adequately investigated. OBJECTIVES: The aim was to assess the accuracy of 5 smart devices in identifying AF compared with a physician-interpreted 12-lead electrocardiogram as the reference standard in a real-world cohort of patients. METHODS: We consecutively enrolled patients presenting to a cardiology service at a tertiary referral center in a prospective, diagnostic study. RESULTS: We prospectively analyzed 201 patients (31% women, median age 66.7 years). AF was present in 62 (31%) patients. Sensitivity and specificity for the detection of AF were comparable between devices: 85% and 75% for the Apple Watch 6, 85% and 75% for the Samsung Galaxy Watch 3, 58% and 75% for the Withings Scanwatch, 66% and 79% for the Fitbit Sense, and 79% and 69% for the AliveCor KardiaMobile, respectively. The rate of inconclusive tracings (the algorithm was unable to determine the heart rhythm) was 18%, 17%, 24%, 21%, and 26% for the Apple Watch 6, Samsung Galaxy Watch 3, Withings Scan Watch, Fitbit Sense, and AliveCor KardiaMobile (P < 0.01 for pairwise comparison), respectively. By manual review of inconclusive tracings, the rhythm could be determined in 955 (99%) of 969 single-lead electrocardiograms. Regarding patient acceptance, the Apple Watch was ranked first (39% of participants). CONCLUSIONS: In this clinical validation of 5 direct-to-consumer smart devices, we found differences in the amount of inconclusive tracings diminishing sensitivity and specificity of the smart devices. In a clinical setting, manual review of tracings is required in about one-fourth of cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationWearable Electronic DevicesHumansFemaleAgedMaleProspective StudiesAlgorithmsElectrocardiography

Stichwörter der Autor:innen

atrial fibrillationdigital healthintelligent ECGsmartwatch

Autor:innen und Institutionen

  • Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Cardiology, University Hospital Basel, Basel, Switzerland; Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: patrick.badertsch…

Förderung

  • Beckman Coulter Foundation
  • Boston Scientific Corporation
  • MicroPort
  • Pfizer
  • Freiwillige Akademische Gesellschaft
  • AstraZeneca
  • Knowles Teacher Initiative
  • Bayer

Zitieren

APA

Mannhart, D., Lischer, M., Knecht, S., du Fay de Lavallaz, J., Strebel, I., Serban, T., Vögeli, D., Schaer, B., Osswald, S., Mueller, C., Kühne, M., Sticherling, C., & Badertscher, P. (2023). Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation. JACC: Clinical Electrophysiology, 9(2), 232-242. https://doi.org/10.1016/j.jacep.2022.09.011

Vancouver

Mannhart D, Lischer M, Knecht S, du Fay de Lavallaz J, Strebel I, Serban T, et al. Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation. JACC: Clinical Electrophysiology. 2023;9(2):232-242. doi:10.1016/j.jacep.2022.09.011

BibTeX
@article{Mannhart2023,
  author = {Mannhart, Diego and Lischer, Mirko and Knecht, Sven and du Fay de Lavallaz, Jeanne and Strebel, Ivo and Serban, Teodor and Vögeli, David and Schaer, Beat and Osswald, Stefan and Mueller, Christian and Kühne, Michael and Sticherling, Christian and Badertscher, Patrick},
  title = {Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation},
  journal = {JACC: Clinical Electrophysiology},
  year = {2023},
  volume = {9},
  number = {2},
  pages = {232--242},
  doi = {10.1016/j.jacep.2022.09.011}
}
Kostenlos starten →